217 related articles for article (PubMed ID: 18951468)
1. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
2. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
Patchenko P; Klepfish A; Trakhtenbrot L; Rothman R; Rachmilewitz EA
Am J Hematol; 2004 Dec; 77(4):420. PubMed ID: 15558793
[No Abstract] [Full Text] [Related]
3. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
[No Abstract] [Full Text] [Related]
4. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O
Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389
[No Abstract] [Full Text] [Related]
5. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
6. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
Alimena G; Breccia M; Mancini M; Ferranti G; De Felice L; Gallucci C; Mandelli F
Leukemia; 2004 Feb; 18(2):361-2. PubMed ID: 14614517
[No Abstract] [Full Text] [Related]
7. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Krämer A; Reiter A; Kruth J; Erben P; Hochhaus A; Müller M; Cross NC; Jones AV; Ho AD; Hensel M
Lancet Oncol; 2007 Jul; 8(7):658-60. PubMed ID: 17613428
[No Abstract] [Full Text] [Related]
8. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP
Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872
[No Abstract] [Full Text] [Related]
9. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
10. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
[No Abstract] [Full Text] [Related]
11. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
12. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
13. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature.
Frustaci A; Breccia M; Cannella L; Stefanizzi C; Alimena G
Leuk Res; 2009 Jan; 33(1):200-1. PubMed ID: 18452989
[No Abstract] [Full Text] [Related]
14. Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
Cervetti G; Carulli G; Galimberti S; Azzarà A; Cannizzo E; Buda G; Orciuolo E; Petrini M
Leuk Res; 2008 Jan; 32(1):191-2. PubMed ID: 17397920
[No Abstract] [Full Text] [Related]
15. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
16. Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia.
Cervetti G; Carulli G; Galimberti S; Azzarà A; Buda G; Orciuolo E; Pelosini M; Petrini M
Leuk Res; 2008 Jan; 32(1):194-5. PubMed ID: 17459473
[No Abstract] [Full Text] [Related]
17. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
18. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
20. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]